AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BUSINESS LINE: Cheap AIDS drugs boost Cipla profile.
The offer by Mumbai-based Cipla Ltd to supply a combination of three AIDS drugs at $350/y/patient to the poor patients in developing countries has pushed the company into limelight.
This move of Cipla has forced the industry majors like GlaxoSmithKline, Bristol-Myers Squibb and Merck & Co to follow suit.
A group of 39 companies decided to withdraw their court case filed in South Africa to prevent South Africa from importing cheap generic versions of their AIDS drugs.
This has cleared the way for Cipla to export the AIDS drugs to …
-
- Ranbaxy withdraws AIDS drugs from South Africa.
-
News wire article from: Asia Africa Intelligence Wire
October 29, 2004
700+ words
-
- GlaxoSmithKline to allow second firm to make AIDS drugs in South Africa.
-
News wire article from: Europe Intelligence Wire
December 10, 2003
700+ words
-
- Row over anti-AIDS drugs overshadows South Africa conference.
-
News wire article from: Europe Intelligence Wire
August 4, 2003
700+ words
-
- RANBAXY RECALLS AIDS DRUGS FROM SOUTH AFRICA (owing to problems in...
-
News wire article from: Asia Africa Intelligence Wire
November 1, 2004
700+ words
-
- Ranbaxy in marketing venture with Adcock Ingram: To sell anti-AIDS drugs in...
-
News wire article from: Asia Africa Intelligence Wire
October 17, 2002
700+ words
